Tags : Receiving

Celltrion and Teva Report Results Updated Results of CT-P6 in

Shots: The study involves assessing of CT-P6 vs reference trastuzumab in 516 patients neoadjuvant period of the study entered the adjuvant treatment period The study resulted in 9 patients (3.3%) in the biosimilar group and 6 patients (2.2%) in the reference group in the ITT population had recurrent or progressive disease @1 year. In adjuvant […]Read More

Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients

Shots: Post EU Approval, Udenyca has received FDA approval on basis of non-inferiority data including its PK, PD and immunogenicity in 600 healthy patients, receiving myelosuppressive CT having cancer Udenyca novel pegfilgrastim-cbqv biosimilar, has received its EU approval on 21 Sep, 2018. In 2017, Pegfilgrastim had $4.5B sales worldwide Udenyca (formerly CHS-1701) is a PEGylated […]Read More